Pharma R&D: the labs of the future turn their data into discovery engines

The pharma data paradox: abundance and fragmentation

Pharmaceutical laboratories today generate unprecedented volumes of data — genomic, proteomic, clinical, process, and imaging data. Yet the majority of this data remains fragmented across dozens of disparate systems: ELNs, LIMS, sequencing platforms, bioinformatics tools, GxP quality systems.

The result: a scientist spends an average of 40% of their time searching for, cleaning and reconciling data rather than analysing it. Consistency errors between systems cost months of delay on regulatory projects. And the tacit knowledge accumulated during a project disappears with the researcher who changes teams.

This paradox — lots of data, little value extracted — is the central challenge of modern pharmaceutical laboratories.

AI in pharma: a promise conditional on data quality

Artificial intelligence is already transforming certain areas of pharmaceutical R&D: in silico toxicity prediction, optimisation of candidate molecules, biomarker identification, acceleration of high-throughput screening. Published results are spectacular — some models reduce candidate molecule pre-selection time by 60%.

But behind these successes lies an absolute requirement: the quality, traceability and interoperability of training data. An AI model trained on poorly annotated, non-traceable, or incompatible data produces non-reproducible results — and results that are unacceptable for a regulatory dossier.

AI in pharma is not an algorithm problem. It is a data infrastructure problem.

The labs of the future: sovereign, traceable and interoperable

The pharmaceutical organisations that succeed in their digital transformation are not those that have adopted the most tools. They are those that have put in place a coherent, governed and interoperable data infrastructure.

This infrastructure rests on three pillars:

Sovereignty — data remains under the organisation's control, hosted in Europe, accessible only to authorised persons according to granular access rules. No dependency on an American hyperscaler whose terms of service can change.

Traceability — every piece of data, every transformation, every result is associated with a verifiable provenance. The GxP audit trail is not a layer added after the fact, but the natural consequence of a system designed for traceability from the start.

Interoperability — data can flow between systems (ELNs, LIMS, CROs, academic partners) via open standards (FHIR, CDISC, OMOP CDM), without silos or manual re-conversions.

Constellab: the platform built for tomorrow's pharmaceutical R&D

Constellab, developed by Gencovery, is the answer to this challenge. It is a sovereign, traceable and interoperable data and AI platform, designed specifically for the needs of life sciences research.

It natively integrates GxP regulatory standards (audit trail, access management, data validation), interoperability standards (FHIR, CDISC, DICOM, HL7, OMOP CDM), and AI analytics capabilities accessible without development expertise.

Constellab is not one more tool to integrate into an existing system. It is the infrastructure that unifies the others: ELNs, LIMS, bioinformatics tools, quality systems — all connected, all data traceable, the whole organisation aligned.

What this changes in practice

For R&D teams, a unified and traceable environment changes the very nature of scientific work. Researchers go from 40% to less than 10% of their time on data management. Experimental results are immediately available for AI analysis. Regulatory dossiers are built in real time rather than reconstructed after the fact.

For organisations, the impact is strategic: shorter development cycles, reduced regulatory risk, valorisation of data accumulated across projects, and the ability to collaborate with CROs and academic partners without losing traceability.

The lab of the future is not the one with the most data. It is the one that does the most with it.